Under the collaboration, Arthrex will market ThermoGenesis’ Res-Q 60 (Res-Q) system technology for use in the preparation of autologous platelet rich plasma (PRP) and bone marrow concentrate (BMC).
The Res-Q technology is a point-of-care platform designed for the preparation of cell concentrates.
The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.
Arthrex offers sports medicine product development and educational services for orthopaedic surgeons.
